0000950170-24-024986.txt : 20240304 0000950170-24-024986.hdr.sgml : 20240304 20240304172956 ACCESSION NUMBER: 0000950170-24-024986 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mylet Johanna CENTRAL INDEX KEY: 0001765988 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 24716296 MAIL ADDRESS: STREET 1: C/O POSEIDA THERAPEUTICS, INC. STREET 2: 4242 CAMPUS POINT COURT, SUITE 700 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472846548 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-03-01 false 0001661460 Poseida Therapeutics, Inc. PSTX 0001765988 Mylet Johanna C/O POSEIDA THERAPEUTICS, INC. 9390 TOWNE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 false true false false Chief Financial Officer false Common Stock 2024-03-01 4 A false 80743 0.00 A 264374 D Common Stock 2024-03-01 4 F false 18091 4.13 D 246283 D Employee Stock Option (Right to Buy) 4.13 2024-03-01 4 A false 111700 0.00 A 2034-02-28 Common Stock 111700 111700 D Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments. Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023. 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter. /s/ Harry J.Leonhardt, Attorney-in-Fact 2024-03-04